Welcome to our dedicated page for Eikon Therapeutics SEC filings (Ticker: EIKN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Eikon Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Eikon Therapeutics's regulatory disclosures and financial reporting.
Eikon Therapeutics provides a detailed update on its clinical-stage pipeline and technology platform. The company describes EIK1001, a TLR7/8 dual-agonist being tested in the Phase 2 TeLuRide-005 NSCLC study, where objective response rate was 63.1% and disease control rate 90.8% across 65 efficacy-evaluable participants as of May 4, 2026, with generally manageable safety alongside pembrolizumab and chemotherapy. A Phase 2/3 registrational melanoma trial (TeLuRide-006) and a Phase 2/3 NSCLC trial (TeLuRide-008) are underway with multiple data readouts and interim analyses planned between the second half of 2026 and the first half of 2027.
The update also highlights EIK1003, a PARP1-selective inhibitor, showing monotherapy objective response rate of 14.3% (7 of 49 evaluable participants) and 24.5% in combination with paclitaxel (13 of 53), with no treatment-related deaths reported. EIK1005, a WRN inhibitor for MSI-high cancers, has early clinical safety data supporting a 50 mg starting dose and a half-life of 9.4 days. EIK1006, an AR antagonist, is progressing through preclinical work toward a projected IND submission by the end of 2026. Eikon emphasizes its single-molecule tracking technology, machine-learning–guided design, and an experienced leadership team.
Eikon Therapeutics, Inc. is a late clinical-stage biopharmaceutical company developing medicines using a proprietary imaging and data platform. For the quarter ended June 30, 2026, it reported a net loss of $88.4 million, compared with $105.2 million a year earlier, driven mainly by research and development expense of $75.5 million and general and administrative expense of $17.9 million.
As of June 30, 2026, Eikon held cash, cash equivalents, and marketable securities of $531.2 million and total assets of $779.6 million, and had an accumulated deficit of about $1.1 billion. Management states these resources are sufficient to fund operations for at least one year. The company completed an IPO in February 2026, issuing 21.2 million shares at $18.00 per share, and converted all redeemable convertible preferred stock into common stock. Eikon discloses a material weakness in internal control over financial reporting linked to a prior-period restatement and outlines plans to remediate it while continuing to advance multiple product candidates, including EIK1001–EIK1006.
Eikon Therapeutics, Inc. reported second quarter 2026 results and extensive clinical progress across its oncology pipeline. The company ended the quarter with $531.2 million in cash, cash equivalents and marketable securities and expects this balance to fund operations into the second half of 2027. Net loss attributable to common stockholders was $88.4 million, compared with $105.2 million a year earlier.
Research and development expenses for the quarter were $75.5 million, up from $69.2 million, reflecting increased clinical trial activity. General and administrative expenses declined sharply to $17.9 million from $40.5 million, primarily due to prior-year impairments that did not recur. Total stockholders’ equity improved to $466.5 million at June 30, 2026, from a deficit of $(879.0) million at December 31, 2025.
Clinically, Eikon highlighted seven accepted abstracts for ESMO 2026 covering all four current clinical candidates, encouraging combination data for EIK1001 in NSCLC and melanoma, and advancing Phase 1/2 programs for PARP1 inhibitors EIK1003 and EIK1004, WRN helicase inhibitor EIK1005, and planned IND submission for AR antagonist EIK1006 by year-end 2026.
FMR LLC and Abigail P. Johnson report a significant ownership position in Eikon Therapeutics Inc. common stock on an amended Schedule 13G. FMR LLC beneficially owns 4,993,906 shares of common stock, representing 9.2% of the outstanding class.
FMR LLC has sole voting power over 4,992,603 shares and sole dispositive power over 4,993,906 shares, with no shared voting or dispositive power. Abigail P. Johnson reports sole dispositive power over the same 4,993,906 shares, but no voting power. One or more other persons may receive dividends or sale proceeds related to these shares, but no other person holds an interest exceeding five percent of the class.
Eikon Therapeutics, Inc. reported that board members Leon Chen, Ph.D. and Joshua Wolfe resigned from its Board of Directors, effective July 31, 2026. The company states that their resignations were not due to any disagreement regarding operations, policies, or practices.
Eikon Therapeutics is a Delaware corporation whose common stock, par value $0.0001 per share, trades on The Nasdaq Stock Market LLC under the symbol EIKN. The report documenting these director changes is signed by Chief Financial Officer Alfred Bowie, Ph.D., on August 3, 2026.
Eikon Therapeutics director Francisco Ma. Fatima reported an initial holding of a stock option covering 85,937 shares of Common Stock. The option has an exercise price of $8.9600 per share and expires on June 4, 2036. According to the vesting terms, 1/48th of the underlying shares vest each month over 48 months, conditioned on continued service.
Eikon Therapeutics, Inc. has appointed Ma. Fatima D. Francisco to its Board of Directors as a Class I director, effective June 15, 2026. She will serve until the company’s 2027 annual stockholder meeting, and will initially sit on the Board’s Compensation Committee.
Under the 2026 non-employee director compensation program, Ms. Francisco will receive an annual cash retainer of $50,000, paid quarterly, and an option to purchase 85,937 shares of common stock at an exercise price of $8.96 per share. The option vests in 48 equal monthly installments, contingent on her continued Board service, and she has signed the company’s standard indemnification agreement.
Eikon Therapeutics filed a current report highlighting new clinical data and an updated corporate presentation. The company presented results from its Phase 2 TeLuRide-005 trial of EIK1001 in first-line stage 4 non-small cell lung cancer and its Phase 1/2 EIK1003 program in advanced solid tumors at the 2026 ASCO meeting.
In NSCLC, EIK1001 plus pembrolizumab and chemotherapy showed a 63.1% objective response rate and 90.8% disease control rate across 65 efficacy-evaluable patients, with the non-squamous cohort reaching a median duration of response greater than 11 months. EIK1003, a highly selective PARP1 inhibitor, produced objective responses both as monotherapy and in combination with weekly paclitaxel, with safety profiles described as generally consistent with expected toxicities and no treatment-related deaths reported.
Eikon Therapeutics, Inc. disclosure shows Innovation Endeavors reporting persons collectively beneficially owned 3,369,519 shares of common stock, representing 6.2% of outstanding shares as of March 31, 2026.
The holdings break down as IE III LP 2,723,226 shares, IE IV LP 498,474 shares, and IE ET SPV 147,819 shares. The filing states shared voting and dispositive power over these holdings and cites 54,138,555 shares outstanding as of March 17, 2026 from the company’s Form 10-K.
Eikon Therapeutics, Inc. disclosure: Roger M. Perlmutter reports beneficial ownership of 2,893,171 shares of Common Stock, representing 5.2% of the class based on 54,138,555 shares outstanding as of March 17, 2026. The position combines 1,190,999 shares held directly, 1,417,315 options exercisable within 60 days of March 31, 2026, and 284,857 shares held by Perlmutter Consulting, Inc.
The filing attributes sole voting and dispositive power over the reported shares to Dr. Perlmutter. The statement is a standard beneficial‑ownership disclosure under Schedule 13G and does not state any transactions or changes in proceeds.